Summary
Nestle India's shares dropped nearly 3% after the FSSAI initiated three legal cases concerning alleged violations in infant nutrition products. The regulator cited promotional claims on NAN Excella Pro Stage 1 and Lactogen Pro 1, and a non-conforming biotin content in a follow-up formula sample.